Patents

274 patents filed by Insilico Medicine and related entities, of which 58 list Alex Zhavoronkov as a named inventor.

0
Total Patents
0
As Named Inventor
Pub. NumberTitleAssigneeDateRole
n/a KINASE INHIBITORS n/a n/a Inventor
n/a METHOD AND MEDICAMENT FOR TREATING ENDOMETRIOSIS n/a n/a Inventor
n/a METHOD AND MEDICAMENT FOR TREATING ENDOMETRIOSIS n/a n/a Inventor
n/a METHOD AND MEDICAMENT FOR TREATING ENDOMETRIOSIS n/a n/a Inventor
n/a METHODS AND SYSTEMS FOR ALCHEMICAL BINDING FREE ENERGY n/a n/a Inventor
n/a Subset conditioning using variational autoencoder with a learnable tensor train induced prior n/a n/a Inventor
n/a Methods of inhibiting kinases n/a n/a Inventor
n/a Subset conditioning using variational autoencoder with a learnable tensor train induced prior n/a n/a Inventor
n/a Kinase inhibitors n/a n/a Inventor
n/a LOCAL STEPS IN LATENT SPACE AND DESCRIPTORS-BASED MOLECULES FILTERING FOR CONDITIONAL MOLECULAR GENERATION n/a n/a Inventor
n/a Analogs for the treatment of disease n/a n/a Inventor
n/a Analogs for the treatment of disease n/a n/a Inventor
n/a Mutual information adversarial autoencoder n/a n/a Inventor
n/a Analogs for the treatment of disease n/a n/a Inventor
n/a ANALOGS FOR THE TREATMENT OF DISEASE n/a n/a Inventor
n/a ANALOGS FOR THE TREATMENT OF DISEASE n/a n/a Inventor
n/a ANALOGS FOR THE TREATMENT OF DISEASE n/a n/a Inventor
n/a ANALOGS FOR THE TREATMENT OF DISEASE n/a n/a Inventor
n/a ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES n/a n/a Inventor
n/a ANALOGS FOR THE TREATMENT OF DISEASE n/a n/a Inventor
n/a METHOD AND MEDICAMENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS n/a n/a Inventor
n/a TLR 9 inhibitors n/a n/a Inventor
n/a Bycyclic JAK inhibitors and uses thereof n/a n/a Inventor
n/a EDGE MESSAGE PASSING NEURAL NETWORK n/a n/a Inventor
n/a SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Inventor
n/a RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY n/a n/a Inventor
n/a SCAFFOLD-ORIENTED UNIVERSAL LINE SYSTEM n/a n/a Inventor
n/a ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS n/a n/a Inventor
n/a DETERMINISTIC DECODER VARIATIONAL AUTOENCODER n/a n/a Inventor
n/a EDGE MESSAGE PASSING NEURAL NETWORK n/a n/a Inventor
n/a SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Inventor
n/a BIOLOGICAL DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK n/a n/a Inventor
n/a TLR inhibitors n/a n/a Inventor
n/a TLR 9 inhibitors n/a n/a Inventor
n/a Methods of inhibiting kinases n/a n/a Inventor
n/a KINASE INHIBITORS n/a n/a Inventor
n/a KINASE INHIBITORS n/a n/a Inventor
n/a SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES n/a n/a Inventor
n/a WORKFLOW FOR GENERATING COMPOUNDS WITH BIOLOGICAL ACTIVITY AGAINST A SPECIFIC BIOLOGICAL TARGET n/a n/a Inventor
n/a WORKFLOW FOR GENERATING COMPOUNDS WITH BIOLOGICAL ACTIVITY AGAINST A SPECIFIC BIOLOGICAL TARGET n/a n/a Inventor
n/a TLR INHIBITORS n/a n/a Inventor
n/a KINASE INHIBITORS n/a n/a Inventor
n/a METHODS OF INHIBITING KINASES n/a n/a Inventor
n/a BICYCLIC JAK INHIBITORS AND USES THEREOF n/a n/a Inventor
n/a WORKFLOW FOR GENERATING COMPOUNDS WITH BIOLOGICAL ACTIVITY AGAINST A SPECIFIC BIOLOGICAL TARGET n/a n/a Inventor
n/a Deep proteome markers of human biological aging and methods of determining a biological aging clock n/a n/a Inventor
n/a TLR inhibitors n/a n/a Inventor
n/a MUTUAL INFORMATION ADVERSARIAL AUTOENCODER n/a n/a Inventor
n/a SUBSET CONDITIONING USING VARIATIONAL AUTOENCODER WITH A LEARNABLE TENSOR TRAIN INDUCED PRIOR n/a n/a Inventor
n/a Deep transcriptomic markers of human biological aging and methods of determining a biological aging clock n/a n/a Inventor
n/a Method of treating senescence with multi-stage longevity therapeutics n/a n/a Inventor
n/a Mutual information adversarial autoencoder n/a n/a Inventor
n/a SYSTEM, METHOD AND SOFTWARE FOR ANALYSIS OF INTRACELLULAR SIGNALING PATHWAY ACTIVATION USING TRANSCRIPTOMIC DATA n/a n/a Inventor
n/a SYSTEMS, METHODS AND SOFTWARE FOR RANKING POTENTIAL GEROPROTECTIVE DRUGS n/a n/a Inventor
n/a SYSTEM, METHOD AND SOFTWARE FOR ANALYSIS OF INTRACELLULAR SIGNALING PATHWAY ACTIVATION USING TRANSCRIPTOMIC DATA n/a n/a Inventor
n/a SYSTEM, METHOD AND SOFTWARE FOR ANALYSIS OF INTRACELLULAR SIGNALING PATHWAY ACTIVATION USING TRANSCRIPTOMIC DATA n/a n/a Inventor
n/a SYSTEM, METHOD AND SOFTWARE FOR PREDICTING DRUG EFFICACY IN A PATIENT n/a n/a Inventor
n/a Systems and methods for communicating with a computer using brain activity patterns n/a n/a Inventor
n/a NOVEL COMPOUNDS AS GLUCOCORTICOID RECEPTOR MODULATORS AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 INHIBITOR COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a TEAD INHIBITOR COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a TEAD INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE TEAD INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a NOVEL COMPOUNDS AS CYCLIC GMP-AMP SYNTHASE INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a WERNER SYNDROME RECQ HELICASE (WRN) INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a SCALABLE FRAMEWORK FOR 3D MOLECULAR DESIGN VIA LANGUAGE MODELING AND REINFORCEMENT LEARNING n/a n/a Assignee
n/a HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF… n/a n/a Assignee
n/a NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a SALT-INDUCIBLE KINASES (SIK) INHIBITORS n/a n/a Assignee
n/a NOVEL COMPOUNDS AS SALT-INDUCIBLE KINASES INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a WERNER SYNDROME RECQ HELICASE (WRN) INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a NOVEL COMPOUNDS AS KRAS INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF KIF18A AND USES THEREOF n/a n/a Assignee
n/a CRBN-BINDING COMPOUNDS AND USES THEREOF n/a n/a Assignee
n/a NOVEL COMPOUNDS AS GLP-1R AGONISTS AND USES THEREOF n/a n/a Assignee
n/a NOVEL COMPOUNDS AS NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a TNIK INHIBITORS FOR THE TREATMENT OF PAIN n/a n/a Assignee
n/a ADVANCED RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY MODELING n/a n/a Assignee
n/a PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCERS n/a n/a Assignee
n/a GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR (GIPR) ANTAGONISTS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF KIF18A AND USES THEREOF n/a n/a Assignee
n/a NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF n/a n/a Assignee
n/a LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SPIRO DERIVATIVES AS WRN INHIBITORS n/a n/a Assignee
n/a NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PRMT5 INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF KIF18A AND USES THEREOF n/a n/a Assignee
n/a MPRO INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Assignee
n/a CDK8/19 DUAL INHIBITORS AND METHODS OF USE THEREOF n/a n/a Assignee
n/a NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE SARS-COV-2 INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a SPIRO DERIVATIVES AS WRN INHIBITORS n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PRMT5 INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a KRAS INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a SYNTHESIS OF MACROCYCLIC COMPOUND AND MEDICAL USE OF MACROCYCLIC COMPOUND n/a n/a Assignee
n/a SUBSTITUTED THIAZOLE COMPOUNDS AS CDK2/4/6 INHIBITORS AND METHODS OF USE THEREOF n/a n/a Assignee
n/a CRYSTALLINE TNIK INHIBITOR AND USES THEREOF n/a n/a Assignee
n/a ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF n/a n/a Assignee
n/a PHARMACEUTICAL FORMULATIONS FOR INHALATION AND USES THEREOF n/a n/a Assignee
n/a CRYSTALLINE BETA-LACTAM DERIVATIVES AND USES THEREOF n/a n/a Assignee
n/a ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a CRYTSALLINE FORMS OF ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF n/a n/a Assignee
n/a BIFUNCTIONAL COMPOUNDS FOR TARGETING PKMYT1 AND METHODS OF USE n/a n/a Assignee
n/a COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES n/a n/a Assignee
n/a NOVEL COMPOUNDS AS PKMYT1 INHIBITORS AND USE THEREOF n/a n/a Assignee
n/a 3CL-PROTEASE INHIBITORS FOR TREATING OR PREVENTING VETERINARY CORONAVIRUS INFECTIONS n/a n/a Assignee
n/a CBL-B INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a NOVEL COMPOUNDS AS MODULATORS OF SODIUM CHANNELS AND USES THEREOF n/a n/a Assignee
n/a NOVEL COMPOUNDS AS GLP-1R AGONISTS AND USES THEREOF n/a n/a Assignee
n/a NOVEL COMPOUNDS AS GLP-1R AGONISTS AND USES THEREOF n/a n/a Assignee
n/a SARS-CoV-2 inhibitors for treating coronavirus infections n/a n/a Assignee
n/a Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof n/a n/a Assignee
n/a Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof n/a n/a Assignee
n/a Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof n/a n/a Assignee
n/a Beta-lactam derivatives for the treatment of diseases n/a n/a Assignee
n/a Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof n/a n/a Assignee
n/a Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof n/a n/a Assignee
n/a Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof n/a n/a Assignee
n/a Lysine acetyltransferase 6A (KAT6A) inhibitors and uses thereof n/a n/a Assignee
n/a TEAD inhibitors and methods of uses thereof n/a n/a Assignee
n/a Beta-lactam derivatives for the treatment of diseases n/a n/a Assignee
n/a Structure-based deep generative model for binding site descriptors extraction and de novo molecular generation n/a n/a Assignee
n/a Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof n/a n/a Assignee
n/a ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF n/a n/a Assignee
n/a METHODS OF MANUFACTURING KINASE INHIBITORS n/a n/a Assignee
n/a SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a SPIRO DERIVATIVE AS KIF18A INHIBITOR n/a n/a Assignee
n/a INHIBITORS OF KIF18A AND USES THEREOF n/a n/a Assignee
n/a ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a STRUCTURE-BASED DEEP GENERATIVE MODEL FOR BINDING SITE DESCRIPTORS EXTRACTION AND DE NOVO MOLECULAR GENERATION n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a HETEROAROMATIC COMPOUNDS AS PKMYT1 INHIBITORS AND USE THEREOF n/a n/a Assignee
n/a PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a HPK1 ANTAGONISTS AND USES THEREOF n/a n/a Assignee
n/a CDK8/19 DUAL INHIBITORS AND METHODS OF USE THEREOF n/a n/a Assignee
n/a INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF n/a n/a Assignee
n/a CBL-B INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF n/a n/a Assignee
n/a METHODS OF MANUFACTURING KINASE INHIBITORS n/a n/a Assignee
n/a INHIBITORS OF TREX1 AND USES THEREOF n/a n/a Assignee
n/a TEAD INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP1) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a SPIRO DERIVATIVE AS KIF18A INHIBITOR n/a n/a Assignee
n/a CBL-B INHIBITORS AND METHODS OF USES THEREOF n/a n/a Assignee
n/a SPIROCYCLIC HPK1 ANTAGONISTS AND USES THEREOF n/a n/a Assignee
n/a INHIBITORS OF KIF18A AND USES THEREOF n/a n/a Assignee
n/a PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES n/a n/a Assignee
n/a BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES n/a n/a Assignee
n/a METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Assignee
n/a SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE n/a n/a Assignee
n/a PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE n/a n/a Assignee
n/a ANALOGS FOR THE TREATMENT OF DISEASE n/a n/a Assignee
n/a ADVERSARIAL FRAMEWORK FOR MOLECULAR CONFORMATION SPACE MODELING IN INTERNAL COORDINATES n/a n/a Assignee
n/a BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES n/a n/a Assignee
n/a METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Assignee
n/a SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Assignee
n/a CDK8/19 DUAL INHIBITORS AND METHODS OF USE n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF n/a n/a Assignee
n/a LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a SUBSTITUTED MONOCYCLIC OR BICYCLIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF n/a n/a Assignee
n/a Retrosynthesis systems and methods n/a n/a Assignee
n/a SCAFFOLD-ORIENTED UNIVERSAL LINE SYSTEM n/a n/a Assignee
n/a ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS n/a n/a Assignee
n/a DETERMINISTIC DECODER VARIATIONAL AUTOENCODER n/a n/a Assignee
n/a SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS n/a n/a Assignee
n/a GRAPH NORMALIZING FLOW FOR HIERARCHICAL MOLECULAR GENERATION n/a n/a Assignee
n/a RETROSYNTHESIS SYSTEMS AND METHODS n/a n/a Assignee
n/a RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY n/a n/a Assignee
n/a TLR 9 INHIBITORS n/a n/a Assignee
n/a GRAPH NORMALIZING FLOW FOR HIERARCHICAL MOLECULAR GENERATION n/a n/a Assignee
n/a METHYLATION DATA SIGNATURES OF AGING AND METHODS OF DETERMINING A METHYLATION AGING CLOCK n/a n/a Assignee
n/a RETROSYNTHESIS SYSTEMS AND METHODS n/a n/a Assignee
n/a Kinase inhibitors n/a n/a Assignee
n/a Scaffold-oriented universal line system n/a n/a Assignee
n/a Workflow for generating compounds with biological activity against a specific biological target n/a n/a Assignee
n/a TLR INHIBITORS n/a n/a Assignee
n/a TLR INHIBITORS n/a n/a Assignee
n/a BICYCLIC JAK INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a BICYCLIC JAK INHIBITORS AND USES THEREOF n/a n/a Assignee
n/a DEEP PROTEOME MARKERS OF HUMAN BIOLOGICAL AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK n/a n/a Assignee
n/a DEEP PROTEOME MARKERS OF HUMAN BIOLOGICAL AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK n/a n/a Assignee
n/a SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES n/a n/a Assignee
n/a DEEP PROTEOME MARKERS OF HUMAN BIOLOGICAL AGING AND METHODS OF DETERMINING A BIOLOGICAL AGING CLOCK n/a n/a Assignee
n/a SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES n/a n/a Assignee
n/a KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT n/a n/a Assignee
n/a Kinase inhibitors n/a n/a Assignee
n/a Entangled conditional adversarial autoencoder for drug discovery n/a n/a Assignee
n/a MUTUAL INFORMATION ADVERSARIAL AUTOENCODER n/a n/a Assignee
n/a MUTUAL INFORMATION ADVERSARIAL AUTOENCODER n/a n/a Assignee
n/a SUBSET CONDITIONING USING VARIATIONAL AUTOENCODER WITH A LEARNABLE TENSOR TRAIN INDUCED PRIOR n/a n/a Assignee
n/a SUBSET CONDITIONING USING VARIATIONAL AUTOENCODER WITH A LEARNABLE TENSOR TRAIN INDUCED PRIOR n/a n/a Assignee
n/a KINASE INHIBITORS n/a n/a Assignee
n/a Subset conditioning using variational autoencoder with a learnable tensor train induced prior n/a n/a Assignee
n/a Withaferin compositions for prevention of aging n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee
n/a n/a n/a n/a Assignee